glecaprevir / pibrentasvir

Details

Generic Name:

Project Status:

Not filed

Therapeutic Area:

Hepatitis C, chronic

Manufacturer:

Pfizer Canada Inc.

Brand Name:

Maviret

Project Line:

Reimbursement Review

Project Number:

NS0023-000

Biosimilar:

Submission Type:

Non-submission

Fee Schedule:

N/A

Indications:

Treatment of chronic hepatitis C virus (HCV) infection in pediatric patients 3 years of age and older and weighing ? 12 kg.

Recommendation Type:

Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.

Last Updated : July 24, 2024